ASCO

Phase 3 Evidence for New Standard in Elderly Glioblastoma Patients

Short-course (hypofractionated) radiotherapy (RT) and temozolomide (TMZ) followed by TMZ significantly prolonged survival versus short-course RT alone in newly diagnosed elderly patients with glioblastoma. These results of a global cooperative group phase 3 trial were 1 of 4 talks selected for the plenary session at the 2016 ASCO Annual Meeting. [ Read More ]

Combination Immunotherapy Makes Progress in Advanced Melanoma

Evidence is mounting that 2 immunotherapies are better than 1 as first-line treatment of advanced melanoma. A phase 3 study showed that nivolumab plus ipilimumab was superior to either agent alone, and a phase 1 study suggests that pembrolizumab can be safely and effectively combined as first-line treatment in this [ Read More ]

Alectinib May Constitute New Frontline Treatment for ALK-Positive NSCLC

Alectinib, an oral ALK inhibitor recently approved for the treatment of advanced ALK-positive non–small cell lung cancer (NSCLC) after crizotinib failure, significantly improved progression-free survival (PFS) compared with crizotinib in the frontline setting, according to data from a head-to-head open-label phase 3 Japanese study. In December 2015, the FDA granted [ Read More ]

Addition of Bcl-2 Inhibitor to MM Regimen Produces Promising Responses in Relapsed/Refractory MM

Venetoclax, an investigational oral selective small molecule Bcl-2 inhibitor, added to bortezomib and dexamethasone resulted in impressive response rates in a phase 1b trial of patients with heavily pretreated relapsed/refractory (RR) multiple myeloma (MM). In the trial, the objective response rate (ORR) was higher among patients whose myeloma cells produced [ Read More ]

Atezolizumab Could Be Start of “Seismic Shift” in Treatment of Metastatic Urothelial Cancer

Atezolizumab has clinically meaningful activity as primary therapy in patients with cisplatin-ineligible locally advanced/metastatic urothelial cancer, according to data from the IMvigor 210 study. Preliminary results also showed encouraging overall survival (OS) data, said Arjun V. Balar, MD, Codirector of the Genitourinary Cancers Program, New York University Langone Medical Center, [ Read More ]

CAR T-Cell Therapy Produces High Response Rates in Refractory B-Cell Malignancies

A durable complete response (CR) was achieved in a high proportion of adult patients with refractory B-cell malignancies who were treated with CD19+ chimeric antigen receptor (CAR) T cells made up of a defined 1:1 ratio of CD8+ and CD4+ cells. The data were presented by Cameron John Turtle, MBBS, [ Read More ]

Opportunities for Shared Decision-Making in Clinical Practice

Although the Institute of Medicine recommends taking a shared decision-making approach to discussions about medical treatments, an overview of evidence at the 2016 ASCO Annual Meeting suggests that clinicians are not very effective in actually following this recommendation. According to Terrance Lynn Albrecht, PhD, this approach requires equal investment by [ Read More ]

Out-of-Pocket Costs Linked to Compliance with Oral Oncologics

Access and adherence to long-term cancer therapies are emerging as major public health issues around the world, as high out-of-pocket costs for oral anticancer agents are linked with noncompliance that can directly affect outcomes.“Solutions should involve increasing access and reducing cost – especially out-of-pocket costs,” said Dawn L. Hershman, MD, [ Read More ]

New Paradigm: Matching Therapy to Molecular Alterations

Ongoing trials at academic centers around the country are testing a new strategy of matching available targeted therapies to molecular abnormalities in tumors instead of treating the site of cancer.MyPathway is one such effort that appears to be paying off, according to preliminary results presented at the 2016 ASCO Annual [ Read More ]

Refining Use of CAR-T in ALL

Chimeric antigen receptor T-cells (CAR-T) have saved lives in some patients with acute lymphoblastic leukemia (ALL) who had run out of other treatment options. This type of immunotherapy is making inroads in other hematologic malignancies as well, but it is still being studied in very sick patients.The downside of CAR-T [ Read More ]

Sign me up!